Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Abstract

Abstract Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.

Keywords

• Maintenance therapy
• Acute myeloid leukemia
• Targeted drugs
• Allogeneic hematopoietic stem cell transplantation